| 摘要 |
The present application relates to novel, anti-C4,4a binder-drug conjugates (ADCs) of N,N-dialkyl auristatins (formula Ia), to effective metabolites of said ADCs, to methods for producing said ADCs, to the use of said ADCs for treating and/or preventing diseases, and to the use of said ADCs for producing pharmaceuticals for treating and/or preventing diseases, in particular hyperproliferative and/or angiogenic diseases, such as cancers. Such treatments can be carried out as monotherapy or in combination with other pharmaceuticals or additional therapeutic measures. |
